Initial target indications are in fertility and pregnancy, where the company seeks to offer the world’s first drug-device combo product to help prevent miscarriages and for IVF luteal support.
In time, this vaginal drug-delivery platform can be used to deliver a wide range of existing and upcoming vaginal therapeutics, including infertility, miscarriage, endometriosis, bacterial vaginosis and cervical cancer.
Sector: MedTech
Raise: £1.5m EIS eligible
PACP Partner Contact: Sharon O’Connor
Latest News
-
November Focus: AI Opportunities With Innovators
AI Investing Trends: The AI startup funding landscape has changed significantly in a short space of time and is currently dominating global venture capital. In 2025 alone, AI startups have attracted a whopping $192.7BN in venture funding, accounting for over half of(52.5%) of all VC investment worldwide. There is, of course, ongoing speculation that it’s …
Continue reading “November Focus: AI Opportunities With Innovators”
-
Opportunities in the Health & Well-Being Sector: Pitch Event Round Up
We were delighted to see another strong attendance of investors at our virtual pitch event last week – thanks to all who joined us and the innovative founders presenting. All the pitching businesses are summarised below, including links to view videos of the pitch presentations and partner contact details to arrange follow up calls with …
Continue reading “Opportunities in the Health & Well-Being Sector: Pitch Event Round Up”
-
Client Spotlight: Fab Materials Secures Pre-Seed Funding
Congratulations to our client, Fab Materials, on securing pre-seed funding from industry angels and SFC Capital to fast-track the launch of its proprietary recycling technology that converts end-of-life textiles into composite boards. Delivering zero waste for the fashion industry, Fab Materials is led by CEO John Somerville, an experienced founder specialising in commercialising new technologies. …
Continue reading “Client Spotlight: Fab Materials Secures Pre-Seed Funding”